E-PaperSun Pharmaceutical Industries Q4 Results Live : profit rise by 33.77% YOY
Sun Pharmaceutical Industries Q4 Results Live : Revenue increased by 9.63% YoY & profit increased by 33.77% YoY
Sun Pharmaceutical Industries Q4 Results Live : Sun Pharmaceutical Industries declared their Q4 results on 22 May, 2024. The topline increased by 9.63% & the profit increased by 33.77% YoY. As compared to the previous quarter the revenue declined by 3.21% and the profit increased by 5.18%.
The Selling, general & administrative expenses declined by 2.71% q-o-q & increased by 5.5% Y-o-Y.
The operating income was down by 12.06% q-o-q & increased by 17.78% Y-o-Y.
The EPS is ₹11.5 for Q4 which increased by 28.38% Y-o-Y.
Sun Pharmaceutical Industries has delivered 0.78% return in the last 1 week, 27.84% return in last 6 months and 22.22% YTD return.
Currently the Sun Pharmaceutical Industries has a market cap of ₹369329.6 Cr and 52wk high/low of ₹1638.85 & ₹932.6 respectively.
As of 23 May, 2024 out of 31 analysts covering the company, 1 analyst has given Sell rating, 5 analysts have given Hold rating, 12 analysts have given Buy rating &13 analysts have given Strong Buy rating.
The consensus recommendation as on 23 May, 2024 was to Buy.
Sun Pharmaceutical Industries Financials
| Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 11982.9 | 12380.7 | -3.21% | 10930.67 | +9.63% |
| Selling/ General/ Admin Expenses Total | 2299.34 | 2363.32 | -2.71% | 2179.55 | +5.5% |
| Depreciation/ Amortization | 650.36 | 622.14 | +4.54% | 671.53 | -3.15% |
| Total Operating Expense | 9643.37 | 9720.38 | -0.79% | 8944.35 | +7.82% |
| Operating Income | 2339.53 | 2660.32 | -12.06% | 1986.32 | +17.78% |
| Net Income Before Taxes | 2815.52 | 3000.35 | -6.16% | 2239.69 | +25.71% |
| Net Income | 2654.58 | 2523.75 | +5.18% | 1984.47 | +33.77% |
| Diluted Normalized EPS | 11.5 | 10.75 | +7.01% | 8.96 | +28.38% |
- Top Gainers
- Top Losers
- 52 Week High
